National Brain Tumor Society (NBTS) recently welcomed an endorsement of the Bolstering Research And Innovation Now (BRAIN) Act (H.R.2767, S.1330) from the American Medical Association (AMA) — the nation’s largest physician organization.
In letters to the bill’s bipartisan sponsors in both the U.S. House of Representatives and Senate, respectively, AMA CEO John Whyte, MD, MPH, cited the legislation’s provisions to strengthen the NCI’s Glioblastoma Therapeutics Network, improve transparency in federal biobank collections, advance immunotherapy research, and ensure brain tumor patients are not excluded from clinical trials — calling these actions a reflection of “a strong commitment to advancing biomedical discovery, strengthening clinical research, and improving patient outcomes.”
“The AMA’s endorsement of the BRAIN Act is a powerful affirmation that the brain tumor community’s priorities are priorities for the entire medical community,” said David Arons, President and Chief Executive Officer of the National Brain Tumor Society. “When the nation’s largest physician organization formally calls on Congress to invest in brain tumor research infrastructure, improve access to cutting-edge treatments, and innovate the way health care is delivered for patients and survivors, it sends a strong signal to policymakers about the importance of this legislation to not just the brain tumor community, but the broader health care ecosystem. We are grateful for the AMA’s support and encouraged by the momentum building around this legislation.”
The AMA endorsement adds to a group of organizations already in support of the BRAIN Act that includes the National Brain Tumor Society, the Alliance for Childhood Cancer, American Brain Tumor Association, Brain Tumor Network, ChadTough Defeat DIPG Foundation, Deadliest Cancers Coalition, Head for the Cure Foundation, Making Headway Foundation, OurBrainBank, Pediatric Brain Tumor Foundation, Society for Neuro-Oncology, Southeastern Brain Tumor Foundation, The Gray Matters Foundation, and The Glioblastoma Research Organization.
The BRAIN Act – introduced with bipartisan, bicameral support in the U.S. Congress – represents the first comprehensive federal legislation specifically designed to address key priority issues from laboratory research to clinical research to diagnosis and survivorship. Since the start of the 119th Congress in January of 2025, the BRAIN Act has garnered 47 cosponsors from both parties in the House and nine in the Senate.
“NBTS is urging Congress to move this landmark bill forward now,” continued Arons. “With Brain Tumor Awareness Month around the corner in May and Glioblastoma Awareness Day on the horizon in July, the BRAIN Act is a uniting piece of legislation that Congress can take urgently needed action on this year.”
NBTS has led advocacy efforts in support of the BRAIN Act since its introduction, mobilizing thousands of patient advocates, survivors, and caregivers across all 50 states and the District of Columbia through its grassroots network and annual Head to the Hill and Advocate from Your State events.
NBTS encourages advocates from across the brain tumor community to contact their members of Congress in support of the BRAIN Act.
Learn more about the BRAIN Act by visiting BrainTumor.org/advocacy/brain-act
